Puma Biotechnology Inc (PBYI) Shares are Up 0.7%

Puma Biotechnology Inc (PBYI) : Traders are bullish on Puma Biotechnology Inc (PBYI) as it has outperformed the S&P 500 by a wide margin of 45.95% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.65%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.7% in the last 1 week, and is up 47.45% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 12.35% and the 50-Day Moving Average is 31.92%. Puma Biotechnology Inc (NYSE:PBYI): stock turned positive on Friday. Though the stock opened at $45.78, the bulls momentum made the stock top out at $48.94 level for the day. The stock recorded a low of $45.75 and closed the trading day at $48.63, in the green by 6.23%. The total traded volume for the day was 833,193. The stock had closed at $45.78 in the previous days trading.


The company Insiders own 20.3% of Puma Biotechnology Inc shares according to the proxy statements. Institutional Investors own 93.58% of Puma Biotechnology Inc shares.

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.